Elisabeth de Vries
Elisabeth de Vries
Professor of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands
Verified email at umcg.nl
Cited by
Cited by
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 365 (9472), 1687-1717, 2005
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
Everolimus for advanced pancreatic neuroendocrine tumors
JC Yao, MH Shah, T Ito, CL Bohas, EM Wolin, E Van Cutsem, TJ Hobday, ...
New England Journal of Medicine 364 (6), 514-523, 2011
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
The lancet 378 (9793), 771-784, 2011
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 …
Early Breast Cancer Trialists' Collaborative Group
The Lancet 378 (9804), 1707-1716, 2011
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …
P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ...
Lancet (London, England) 383 (9935), 2014
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo …
ME Pavel, JD Hainsworth, E Baudin, M Peeters, D Hörsch, RE Winkler, ...
The Lancet 378 (9808), 2005-2012, 2011
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ...
The Lancet Oncology 18 (3), e143-e152, 2017
Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
RJ Scheper, HJ Broxterman, GL Scheffer, P Kaaijk, WS Dalton, ...
Cancer research 53 (7), 1475-1479, 1993
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
M Müller, C Meijer, GJ Zaman, P Borst, RJ Scheper, NH Mulder, ...
Proceedings of the National Academy of Sciences 91 (26), 13033-13037, 1994
Radiolabeled amino acids: basic aspects and clinical applications in oncology
PL Jager, W Vaalburg, J Pruim, EGE De Vries, KJ Langen, DA Piers
Journal of nuclear medicine 42 (3), 432-445, 2001
Evidence based selection of housekeeping genes
HJM De Jonge, RSN Fehrmann, ESJM de Bont, RMW Hofstra, F Gerbens, ...
PloS one 2 (9), e898, 2007
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 386 (10001), 1341-1352, 2015
Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer
EC Dijkers, TH Oude Munnink, JG Kosterink, AH Brouwers, PL Jager, ...
Clinical Pharmacology & Therapeutics 87 (5), 586-592, 2010
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical …
NI Cherny, R Sullivan, U Dafni, JM Kerst, A Sobrero, C Zielinski, ...
Annals of Oncology 26 (8), 1547-1573, 2015
A review on CXCR4/CXCL12 axis in oncology: no place to hide
UM Domanska, RC Kruizinga, WB Nagengast, H Timmer-Bosscha, ...
European journal of cancer 49 (1), 219-230, 2013
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
H Pan, R Gray, J Braybrooke, C Davies, C Taylor, P McGale, R Peto, ...
New England Journal of Medicine 377 (19), 1836-1846, 2017
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer
MT Meinardi, JA Gietema, WTA Van der Graaf, DJ Van Veldhuisen, ...
Journal of Clinical Oncology 18 (8), 1725-1732, 2000
Metformin: taking away the candy for cancer?
M Jalving, JA Gietema, JD Lefrandt, S de Jong, AKL Reyners, ROB Gans, ...
European journal of cancer 46 (13), 2369-2380, 2010
A potential role of macrophage activation in the treatment of cancer
AH Klimp, EGE De Vries, GL Scherphof, T Daemen
Critical reviews in oncology/hematology 44 (2), 143-161, 2002
The system can't perform the operation now. Try again later.
Articles 1–20